Keyphrases
1H-MRS
100%
Glioblastoma
100%
GL261
100%
Antitumor Immune Response
100%
Temozolomide
100%
Immune Enhancement
100%
Metronomic Schedule
100%
Tumor
40%
Lymphocytes
20%
Therapy Response
20%
Oscillatory Activity
20%
Brain Tumor
10%
Metabolomics
10%
Macrophages
10%
Microglia
10%
Poor Prognosis
10%
Host Immune Response
10%
Machine Learning Approach
10%
Tumor Samples
10%
Challenge Test
10%
C57BL
10%
Immune Process
10%
Programmed Death-ligand 1 (PD-L1)
10%
Non-responders
10%
Glioblastoma multiforme
10%
Tumor-bearing Mice
10%
Response Pattern
10%
Follow-up Strategy
10%
Iba1
10%
Rechallenge
10%
Response-outcome
10%
CD3+ Cells
10%
Histopathological Correlation
10%
Oscillatory Patterns
10%
Aggressive Therapy
10%
Mouse Survival
10%
Further Treatment
10%
Administration Regimen
10%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Glioblastoma
100%
Temozolomide
100%
C57BL 6 Mouse
10%
Intracranial Tumor
10%
CD3 Antigen
10%
Veterinary Science and Veterinary Medicine
Temozolomide
100%
Mouse
40%
Lymphocyte
20%
Protocerebrum
10%
Macrophage
10%
Microglia
10%